BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38449417)

  • 1. [A Case Report of Metastatic Breast Cancer with Peritoneal Metastasis and Massive Ascites Responding to CDK4/6 Inhibitor(Palbociclib)].
    Yao S; Goi T; Takahashi M; Kono H; Yokoi S; Maeda H
    Gan To Kagaku Ryoho; 2024 Feb; 51(2):214-216. PubMed ID: 38449417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report.
    Jung SU; Jung M; Choi JH; Jeon CW
    Medicine (Baltimore); 2021 Apr; 100(14):e25175. PubMed ID: 33832078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
    Ishiguro A; Tanimoto A; Ito K; Ohigashi A; Kato H; Abe M; Kubota R; Chiba R; Matsunami O; Narita Y
    Gan To Kagaku Ryoho; 2021 May; 48(5):697-699. PubMed ID: 34006717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
    Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
    N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
    Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
    Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
    Turner NC; Liu Y; Zhu Z; Loi S; Colleoni M; Loibl S; DeMichele A; Harbeck N; André F; Bayar MA; Michiels S; Zhang Z; Giorgetti C; Arnedos M; Huang Bartlett C; Cristofanilli M
    J Clin Oncol; 2019 May; 37(14):1169-1178. PubMed ID: 30807234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
    Nakamura A; Shigekawa T; Asakawa H; Park K; Baba N
    Gan To Kagaku Ryoho; 2021 Oct; 48(10):1251-1254. PubMed ID: 34657057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?].
    Vazquez L; Arnaud A; Grenier J; Debourdeau P
    Bull Cancer; 2021 May; 108(5):544-552. PubMed ID: 33820647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
    Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
    Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoidosis-like reaction during palbociclib treatment for metastatic breast cancer: A case report.
    Stoffaës L; Dumazet A; Deslee G; Mohammad Muttaqi Z; Didier K; Botsen D
    Breast J; 2020 Jun; 26(6):1239-1241. PubMed ID: 32275106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
    Turner NC; Slamon DJ; Ro J; Bondarenko I; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; André F; Puyana Theall K; Huang X; Giorgetti C; Huang Bartlett C; Cristofanilli M
    N Engl J Med; 2018 Nov; 379(20):1926-1936. PubMed ID: 30345905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
    Murakami F; Horimoto Y; Shimizu H; Tada K; Yamaji K; Tamura N; Saito M
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):214-217. PubMed ID: 33587021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
    Framarino-Dei-Malatesta M; Chiarito A; Bianciardi F; Fiorelli M; Ligato A; Naso G; Pecorella I
    BMC Cancer; 2019 Jan; 19(1):36. PubMed ID: 30621656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
    Gao HF; Zhang JS; Zhang QZ; Zhu T; Yang CQ; Zhang LL; Yang M; Ji F; Li JQ; Cheng MY; Niu G; Wang K
    Front Endocrinol (Lausanne); 2021; 12():659537. PubMed ID: 34690920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions.
    Lee J; Park HS; Won HS; Yang JH; Lee HY; Woo IS; Shin K; Hong JH; Yang YJ; Chun SH; Byun JH
    Cancer Res Treat; 2021 Apr; 53(2):409-423. PubMed ID: 33138346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Case of Recurrent Breast Cancer with Multiple Bone Metastasis Effectively Treated by CDK4/6 Inhibitor in Addition to Aromatase Inhibitor].
    Satoh E; Hara M; Uehira D; Yonekura K; Murakata A; Ohinata R; Toyofuku Y; Tanami H; Osanai T; Sugano N; Sakoma T
    Gan To Kagaku Ryoho; 2022 Dec; 49(13):1491-1493. PubMed ID: 36733112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.